Cerebrospinal fluid penetration of very high-dose meropenem: a case report
Abstract Background Standard dosing of meropenem (2 g t.i.d.) produces CSF concentrations of only 1-2 mg/L which is inferior to the clinical breakpoint for most Gram-negative bacteria. There is therefore concern that dosing must be increased in order to achieve therapeutic CSF concentrations for bac...
I tiakina i:
Ngā kaituhi matua: | Thomas Kerz (Author), Friederike D. von Loewenich (Author), Jason Roberts (Author), Axel Neulen (Author), Florian Ringel (Author) |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
BMC,
2018-12-01T00:00:00Z.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ngā tūemi rite
-
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
mā: Eric H. Decloedt, me ētahi atu.
I whakaputaina: (2021) -
Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion
mā: Christoph Tiede, me ētahi atu.
I whakaputaina: (2021) -
Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study
mā: Christina König, me ētahi atu.
I whakaputaina: (2023) -
Cerebrospinal Fluid
I whakaputaina: (2022) -
Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis
mā: Melanie R. Nicol, me ētahi atu.
I whakaputaina: (2019)